Login or sign up
For business
Average ratingAverage
3.8/ 5

Based on 10 reviews

520%
440%
340%
20%
10%
Ask AI

Ask AI about Perlara

Generated with AI from 10 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Latifa Alali
Reviews 1

I had a fantastic experience with Perlara. Their services exceeded my expectations in every aspect. The team is friendly, knowledgeable, and always ready to help. I am extremely satisfied with the results and would highly recommend Perlara to anyone looking for high-quality services.

Phil Price
Reviews 1

I recently started using Perlara for my business and I must say that I am very impressed. Their team is highly skilled and they provide excellent solutions. The customer support is top-notch and they are always available to assist. I would highly recommend Perlara to anyone looking for reliable services.

Dierdre Cherry
Reviews 1

I recently started using Perlara's services and I am extremely happy with the results. Their team is highly professional and knowledgeable. The customer support is excellent and they always respond promptly to any queries I have. I highly recommend Perlara to anyone looking for a reliable and efficient company.

Jake Kirsch
Reviews 1

I have been working with this company for quite some time now and I must say that they have impressed me with their professionalism and dedication. Their services are top-notch and they have helped me achieve great results. I highly recommend their services to anyone in need.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Perlara

Perlara, PBC is the first Public Benefit Corporation accelerating precision drug discovery for 5,000+ rare genetic diseases. PLab uses a platform of CRISPR-engineered animal models (yeast, nematodes, fruit flies and zebrafish) in whole-organism phenotypic screens to generate disease-reversing orphan drug candidates much faster and cheaper than traditional in vitro and cell-based approaches. Their lead discovery programs are Niemann-Pick Type C, a lysosomal storage disorder first described nearly a century ago, and NGLY1 Deficiency, a congenital disorder of glycosylation first diagnosed last year. Their initial pipeline includes, among others, additional lysosomal storage disorders, e.gs, Batten and Mucolipidosis IV, mitochondrial diseases, e.g., Leigh, and peroxisomal biogenesis disorders, e.g., Zellweger.